PTK2 and non-small cell lung carcinoma: Overall, targeting SRC/FAK might be a promising way to develop effective therapies for LKB1-mutated NSCLC, although further studies are needed to assess their real efficacy in human clinical trials and in different subtypes of LKB1-mutated or co-mutated NSCLC (155).